Jeffrey N. Myers

The paper identifies enhancer subtypes in cancer cell lines and tumors, revealing distinct epigenetic patterns and potential therapeutic targets.

This study shows that suppressing SPP1 improves cisplatin sensitivity and inhibits tumor invasion and metastasis in NRF2-hyperactivated cisplatin-resistant HNSCC.

This study clarifies that NOTCH1 acts as a tumor suppressor in head and neck cancer, reducing cancer stem cells and improving prognosis, despite conflicting prior reports.

This study shows that p53 activity persists in HPV+ HNSCC tumors with WT TP53, leading to better survival and therapeutic vulnerabilities.

This paper identifies PI3K pathway activation in Nrf2-driven cisplatin-resistant HNSCC and shows that gedatolisib inhibits tumor growth and re-sensitizes cells to cisplatin.

This study shows cigarette smoke exposure drives aggressive head and neck cancer by altering oxidative stress response and immunity through Nrf2 activation and metabolic reprogramming.